Michigan’s Bio-Industry Strategic Roadmap to be Updated

May 29, 2024

Charting the Future of Michigan’s Biosciences Industry

MichBio, the association for Michigan’s biosciences industry, announced during the 2024 Mackinac Policy Conference that it is launching a statewide effort to update the Michigan Bio-Industry Roadmap for Success. The Roadmap is a strategic plan released in early 2016 for growing Michigan’s biosciences industry into a global leader. 



“Michigan’s bio-industry is at a critical point given the rapidly changing dynamics in the worldwide marketplace and healthcare delivery landscape”, remarked Stephen Rapundalo, MichBio President and CEO. “While our statewide bio-industry cluster has witnessed good growth in recent years, other U.S. regions, many with lesser industry footprints and research innovation strength than Michigan, have been far more aggressive and successful in developing their life sciences hubs. It is imperative to develop a shared and executable vision for supporting Michigan’s bio-industry that can retain both our STEM and trades talent in high-wage jobs.” 

The updated Roadmap is an operational “game plan” to enable growth over the next five years. The planning effort will identify key strategies to expand the different sectors that make up the bio-industry including pharmaceuticals, medical products and technologies, research and testing, agricultural/industrial biotechnology, health technologies, and bioscience distribution. In addition, the initiative will define priorities for spurring innovation, improving the business climate and capital access, and developing talent for all skill levels. 


“It is important to note that the biosciences are the one industry where Michigan has all the needed ingredients to realize economic success. This begins with our world-class research institutions that deliver discoveries and serve as the substrate for commercialization, and ultimately, the development of life-changing treatments for patients,” said Britany Affolter-Caine, University Research Corridor (URC) Executive Director. “A roadmap that integrates stakeholders from across the state is critical to sustain, much less grow, an R&D and biomanufacturing ecosystem that is the envy of others.” 


The road mapping effort will be overseen by an executive steering committee comprised of bio-industry experts from around Michigan: 


Outreach to bio-industry stakeholders is planned in the form of a statewide listening tour, interviews, focus groups, and surveys. Data gathered will validate key strategic themes and areas, identify new unmet needs and growth opportunities, and help develop policy proposals for legislative action. Existing MichBio workgroups (Committees) will support the steering group in developing the Roadmap. The final report will include recommendations around goals, performance measures and responsible parties for delivering outcomes. 

“Accelerating the success of Michigan’s life science industry requires a mission-driven mindset to nurture growth,” says Rapundalo. “Our core challenge – and great opportunity – is to bring synergies together around our assets and capabilities, direct them in a manner that empowers all stakeholders, and allows the industry to flourish. The Roadmap seeks to be the beacon for executing on that mission. The time for action is now.” 


———————— 


MichBio is the only statewide trade association committed to driving growth in Michigan’s biosciences industry and its many sectors, including agricultural/industrial biotech, medical devices, pharmaceuticals, academic/clinical research, testing and research services, healthcare and information technologies, and bioscience products distribution. MichBio members include bioscience companies, research institutions, manufacturing suppliers and service providers, and related organizations. MichBio is here to support Michigan’s bioscience researchers, innovators, and producers, as well as those in the broader ecosystem that serve to sustain them. Through advocacy, programming, connecting, and business resources we help the state’s biosciences community thrive. For more information, visit www.michbio.org or follow us on LinkedIn and X. 

RECENT ARTICLES

MichBio Joins in Opposition to Proposed Changes to MCPA

May 9, 2025
Recent changes to Michigan's consumer protection laws have sparked debate, and a coalition of Michigan industry groups have joined to oppose the removal of the regulatory compliance exemption under the Michigan Consumer Protection Act (MCPA) . This exemption previously shielded regulated industries from lawsuits under the MCPA, but a recent bill, SB 134 , would repeal it. MichBio and coalition partners believe that this could lead to increased litigation and costly lawsuits for businesses and submitted their concerns and opposition to the Senate Finance, Insurance & Consumer Protection Committee. This legislation is a response to the Michigan Supreme Court 1999 case decision in Smith v. Globe Life Insurance Company , which supposedly weakened the power of the Michigan Consumer Protection Act by exempting many industries, like pharmaceuticals, from liability, leaving residents ill-protected from scams and other deceptive activity. The MCPA currently does not apply to “[a] transaction or conduct specifically authorized under laws administered by a regulatory board or officer acting under statutory authority of this state or the United States.” In its Smith v. Glove Life Ins. Co. and Liss v. Lewiston-Richards, Inc. decisions, the Michigan Supreme Court (MSC) interpreted this to mean the following: if a person or company is licensed or approved to engage in a certain business or profession, and the transaction at issue falls within the scope of that license, that conduct falls outside the MPCA. While these rulings do not give a complete exemption to regulated industries from the MCPA (i.e., if the person or business is operating outside the scope of the occupation or profession, there could be an MCPA claim), they do provide protections. Attorney General Nessel, who testified in support of the legislation in the prior session , launched an investigation into insulin manufacturer Eli Lilly and asked the Michigan Supreme Court to reconsider the two previous MSC rulings that hinder the Department’s ability to take action against drug manufacturers and other regulated/licensed entities under the MCPA. Under the 1999 and 2007 decisions, Nessel is unable to even begin an investigation into Eli Lilly because it is regulated by both the Federal Drug Administration and the Michigan Board of Pharmacy, even though neither have authority over pricing. The Court heard oral arguments in that matter earlier this year .

MichBio Meets with Legislators Regarding Proposed 340B Legislation

May 9, 2025
Michigan’s legislature is considering two bills, SB 94 and SB 95 related to the federal 340B Drug Pricing Program and both bills are expected to be deliberated by the House Health Policy Committee in due course. These bills, passed by the Michigan Senate, aim to prohibit drug manufacturers from restricting hospitals' access to discounted drugs under 340B. The 340B program was originally intended to help low-income and uninsured patients access affordable medications by requiring drug manufacturers to provide discounts to safety-net providers. However, misuse and abuse of this well-intentioned but ballooning program is driving up costs for patients, taxpayers, employers, and everyone who pays for healthcare. The 340B program enables participating hospitals to purchase medications at significant discounts and sell them to plan sponsors at the prevailing rate, a “buy low, sell high” scheme that results in profits at the expense of working families. There is no guarantee that 340B profits are passed to vulnerable patients in local communities, while raising prices due to incentives for steep markups on medications, lost rebates, health system consolidation, and incentives to prescribe higher-cost drugs and fewer biosimilars. MichBio spent time alongside representatives from member companies and our national organization, BIO, educating key legislators about 340B and specifically raised concerns about the potential impact of 340B programs on drug pricing and innovation. We and our partners maintain that any changes to the 340B program should be comprehensive and address systemic issues, such as transparency, diversion, and duplicate discounts, ideally at the federal level. MichBio continues to work to ensure that any changes to the program do not negatively affect patients, providers, and the industry as a whole.

Citizen Petition Filed Against FDA's Call for Animal Testing Alternatives

May 9, 2025
A citizen petition has been filed objecting to the FDA's recent call for alternatives to animal testing, arguing that it could lead to reliance on unvalidated methods and pose risks to human subjects. The petition suggests that the FDA's move to embrace alternatives may not be fully vetted and could jeopardize human safety. Moreover, it calls on the FDA to amend its regulations, publish a guidance document on non-animal methods, and incorporate encouragement for their use in existing and future guidance documents. As background, on April 10, 2025, the FDA announced its intent to phase out the use of animal testing in the development of certain drugs and biologics. To help bring this “paradigm shift in drug evaluation” to fruition as outlined in a roadmap , FDA is offering pharmaceutical manufacturers incentives such as faster approval times and reduced testing requirements if they leverage emerging technologies that the agency believes hold the promise of cheaper, safer, and more ethical drug development processes. The FDA’s sights are currently set on obviating the need for animal testing specifically in monoclonal antibody trials. However, the agency emphasized in the announcement its desire to expand its efforts to all future applicable use cases. Opponents of animal testing have celebrated the FDA shift as a significant win. However, the fact is that such changes have been in the works for decades, as many research efforts in both the public and private sectors have focused on developing alternative testing technologies and models. The petition asks that FDA stay its implementation of the April 10 policy, saying it should not be put into practice without a public comment period and an independent expert review of the proposed alternatives to animal testing. Without public comment, the organization says the change is a rulemaking that doesn’t follow the requirements of the Administrative Procedure Act. Notwithstanding the petition, the FDA plans to host a public workshop later 2025 to discuss the roadmap and aims to launch the pilot program allowing select monoclonal antibody developers to use a primarily non-animal-based testing strategy.